ITGA2

Across TCGA pan-cancer cohorts, ITGA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ITGA2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ITGA2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ITGA2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, PDAC, and GBM are the cancer types where ITGA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.300	0.866	.006	12	view →
PDAC	DFS	Median	All	0.682	0.898	.019	7	view →
GBM	DFS	Median	All	0.258	0.493	.012	3	view →
HNSC	OS	Median	II,III,IV	1.000	0.954	.023	2	view →
LSCC	DFS	Median	All	0.905	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ITGA2–LUAD (OS)

Open the LUAD breakdown →